Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Intervalo de ano de publicação
2.
Ann Neurol ; 63(5): 632-41, 2008 May.
Artigo em Inglês | MEDLINE | ID: mdl-18384166

RESUMO

OBJECTIVE: Neonatal stroke is associated with the N-methyl-D-aspartate receptor (NMDAR)-mediated excitotoxic brain injury. Src family kinases (SFKs) are considered to be the molecular hub for NMDAR regulation. We determined the relationship between SFKs activation and NMDAR tyrosine phosphorylation after neonatal hypoxia-ischemia (HI) and investigated the neuroprotective potential of a selective SFKs inhibitor, PP2 (4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo [3, 4-d] pyramidine), against neonatal brain ischemic injury. METHODS: The Rice-Vannucci model was adapted for neonatal HI injury in postnatal day 7 CD1 mice. SFKs activity in the postsynaptic densities was measured by Western blot. NMDAR tyrosine phosphorylation and their association with SFKs were determined by coimmunoprecipitation. Brains from animals treated with PP2 or its inactive analog, PP3, were examined histologically with cresyl violet and iron stain to assess the degree of damage. RESULTS: Neonatal HI resulted in a rapid and transient increase in tyrosine phosphorylation of NMDAR subunits NR2A and NR2B. This upregulation correlated with the enhanced association of Fyn and Src with NR2A and NR2B. SFKs were activated in the postsynaptic densities after HI. Inhibition of SFKs with PP2 attenuated brain injury after neonatal HI, whereas PP3 did not protect the brain from the HI insult. INTERPRETATION: SFKs may play an important role in NMDAR-mediated excitotoxicity and downstream events leading to neuronal death after neonatal HI. Inhibition of SFKs may provide protection against neonatal stroke. Rather than blockade of NMDAR after HI in the developing brain, it may be safer and more beneficial to manipulate components of the NMDAR signaling complex at the postsynaptic density.


Assuntos
Isquemia Encefálica/tratamento farmacológico , Isquemia Encefálica/metabolismo , Pirimidinas/administração & dosagem , Receptores de N-Metil-D-Aspartato/metabolismo , Quinases da Família src/administração & dosagem , Quinases da Família src/antagonistas & inibidores , Animais , Animais Recém-Nascidos , Isquemia Encefálica/patologia , Ativação Enzimática/efeitos dos fármacos , Camundongos , Fármacos Neuroprotetores/administração & dosagem , Transdução de Sinais/efeitos dos fármacos , Resultado do Tratamento
3.
Noise Health ; 7(29): 24-30, 2005.
Artigo em Inglês | MEDLINE | ID: mdl-17478966

RESUMO

Both the antioxidant, n-l-acetyl cysteine (L-NAC) and the Src inhibitor, KX1-004, have been used to protect the cochlea from hazardous noise. To date, KX1-004 has only been used locally on the round window. In the current study, the two drugs were administered systemically. LNAC was delivered intraperitoneally at a dose of 325 mg/kg while KX1-004 was administered subcutaneously at a dose of 50 mg/kg. The noise exposure consisted of a 4 kHz octave band of noise at 100 dB SPL for 6 hours/day for 4 days. The drugs were administered once each day, 30 minutes prior to the onset of the noise exposure. The animals' hearing was estimated using the evoked response records from surgically-implanted chronic electrodes in the inferior colliculi. Animals treated with LNAC and KX1-004 had from 10 to 20 dB less temporary threshold shift at day 1 and an average 10 dB less permanent threshold shift by day 21 when compared to control saline treated animals. There were no significant side effects (i.e.: appetite loss, weight loss, lethargy, etc.) related to either of the drug treatments. KX1-004 produced at least as much protection as L-NAC, but at a significantly lower concentration.


Assuntos
Acetilcisteína/administração & dosagem , Potenciais Evocados Auditivos/efeitos dos fármacos , Glutationa/administração & dosagem , Perda Auditiva Provocada por Ruído/prevenção & controle , Ruído/efeitos adversos , Inibidores de Proteínas Quinases/administração & dosagem , Espécies Reativas de Oxigênio/efeitos adversos , Quinases da Família src/antagonistas & inibidores , Acetilcisteína/farmacologia , Animais , Apoptose/efeitos dos fármacos , Limiar Auditivo/efeitos dos fármacos , Chinchila , Modelos Animais de Doenças , Eletrodos , Exposição Ambiental/efeitos adversos , Glutationa/farmacologia , Perda Auditiva Provocada por Ruído/tratamento farmacológico , Colículos Inferiores/fisiologia , Injeções Intraperitoneais , Inibidores de Proteínas Quinases/farmacologia , Fatores de Tempo , Quinases da Família src/administração & dosagem , Quinases da Família src/farmacologia
4.
Reproduction ; 128(4): 387-93, 2004 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-15454633

RESUMO

Prior to fertilization, the spindle of vertebrate eggs must remain stable and well organized during the second meiotic meta-phase arrest (MII). In a previous study we have determined that the completion of meiosis is a Src family kinase (SFK)-dependent event. In the current study we have used the SFK inhibitors, SU6656 and PP2, and demonstrated that inhibition of SFKs caused the formation of a disorganized spindle. The observation that proper organization of an MII spindle is an SFK-dependent process, combined with our previous finding that Fyn kinase is localized at the microtubules (MTs), prompted us to examine the potential role of Fyn in MT signaling. Our results show an association between Fyn and tubulin, the ability of Fyn to phosphorylate tubulin in vitro and stimulation of meiosis completion by injection of a constitutively active form of Fyn (CAF). We suggested that SFKs mediate significant functions during the organization of the MII spindle. In view of CAF injection experiments, and of the pronounced concentration of Fyn kinase at the spindle, we propose that Fyn may play an important role in some aspects of the spindle functions, possibly those involving the MTs.


Assuntos
Óvulo/metabolismo , Proteínas Proto-Oncogênicas/metabolismo , Tubulina (Proteína)/metabolismo , Animais , Células Cultivadas , Feminino , Indóis/farmacologia , Meiose , Microinjeções , Microscopia Confocal , Microtúbulos/ultraestrutura , Óvulo/ultraestrutura , Proteínas Proto-Oncogênicas/análise , Proteínas Proto-Oncogênicas c-fyn , Pirimidinas/farmacologia , Ratos , Ratos Wistar , Fuso Acromático/metabolismo , Fuso Acromático/ultraestrutura , Sulfonamidas/farmacologia , Tubulina (Proteína)/análise , Quinases da Família src/administração & dosagem , Quinases da Família src/antagonistas & inibidores , Quinases da Família src/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...